Appropriate laboratory assessmant as a critical facet in the proper diagnosis and classification of von Willebrand disorder

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 2, 2001, Pages 299-319

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Diagnosis; Laboratory assessment; Review; von Willebrand disease; von Willebrand disorder; von Willebrand factor; VWD; VWF

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8; COLLAGEN; POLYMER; RISTOCETIN; VON WILLEBRAND FACTOR;

ANTIGEN DETECTION; ARTICLE; BINDING AFFINITY; BIOASSAY; BLEEDING TIME; BLOOD CLOTTING PARAMETERS; CLINICAL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; LABORATORY TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE; CLASSIFICATION; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DIFFERENTIAL DIAGNOSIS; PATHOPHYSIOLOGY; REVIEW;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0034742637     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0135     Document Type: Article

References (83)

1. Impact, diagnosis and treatment of von Willebrand disease
2. Commentary: A new classification for von Willebrand disease
3. A revised classification of von Willebrand disease
4. Structure and function of von Willebrand factor
5. Guidelines for the diagnosis and management of von Willebrand disease
6. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease
7. Review: Laboratory methods for the genetic diagnosis of bleeding disorders
8. von Willebrand factor (VWF) database
9. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease
10. Desmopressin: A nontransfusional treatment of haemophilia and von Willebrand disease
11. Post-DDAVP thrombocytopenia in Type 2B von Willebrand disease is not associated with platelet consumption: Failure to demonstrate glycocalicin increase or platelet activation
12. Laboratory testing, diagnosis and management of von Willebrand's disease: Current practice in Australasia
13. Laboratory assays for von Willebrand Factor: Relative contribution to the diagnosis of von Willebrand's disease
14. Laboratory testing for von Willebrand's disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey
15. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disease: Results from the second Australasian laboratory survey
16. Review: Assessment of haemostatic function: Follow up evaluation of abnormal 'screening' coagulation tests and possible outcomes
17. Evaluation of mild disorders and easy bruising
18. Congenital disorders of platelet function: Disorders of signal transduction and secretion
19. Clinching the diagnosis: Assessment of hemostatic function
20. Comparative evaluation of 17 commercial APTT reagents
21. Screening for von Willebrand disease with a new analyser using high shear stress: A study of 60 cases
22. Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear rates
23. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease
24. Comparison of the O'Brien filter test and the PFA-100 platelet analyser in the laboratory diagnosis of von Willebrand's disease
25. The bleeding time does not predict surgical bleeding
26. Bleeding time and bleeding: An analysis of the relationship of the bleeding time test with parameters of surgical bleeding
27. Platelet function testing
28. Biorheology
29. Screening for von Willebrand's disease: Use of a novel platelet function analyser (PFA-100) with high sensitivity to disturbances in von Willebrand factor
30. Description of an in-vitro platelet function analyser: PFA-100
31. Preliminary data from a field trial of the PFA-100™ system
32. Characterisation of an in-vitro platelet function analyser, PFA-100™
33. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis
34. The platelet function analyser (PFA-100): A novel in-vitro system for evaluation of primary haemostasis in children
35. Use of the PFA-100 in the assessment of primary, platelet related hemostasis in a pediatric setting
36. PFA-100 system: A new method for assessment of platelet dysfunction
37. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center
38. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function
39. Low platelet alpha2betal levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system
40. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion
41. Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: Efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies
42. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: A review of analytical variables, benefits and limitations
43. Assessment of platelet function assays
44. Usefulness of thrombelastography in assessment of trauma patient coagulation
45. The xylum clot signature analyser: A dynamic flow system that simulates vascular injury
46. A new automated method for von Willebrand factor antigen measurement using latex particles
47. Possibility of false negative VWD, or potential VWD misclassification, using LIA technology and due to presence of rheumatoid factor
48. Evaluation of a new automated ELISA test for von Willebrand factor using two monoclonal antibodies
49. Laboratory assessment of von Willebrand factor: Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition weight VWF forms
50. von Willebrand factor: Measuring its antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems
51. Ristocetin. A new tool in the investigation of platelet aggregation
52. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation
53. A method for assaying von Willebrand's factor (ristocetin cofactor)
54. Laboratory assessment of von Willebrand factor: Altered interpretation of laboratory data, and altered diagnosis of von Willebrand's disease, as influenced by the use of different VWF assays and assay conditions
55. An immunoradiometric assay for human factor VIII von Willebrand factor (VIII: VWF) using a monoclonal antibody that defines a functional epitope
56. A two-site, monoclonal antibody based immunoassay for von Willebrand factor - Demonstration that VWF function resides in a conformational epitope
57. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use
58. Assays for von Willebrand factor functional activity: A UK NEQAS Survey
59. Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrands disease (VWD) and discrimination of VWD subtypes depends on collagen source
60. Discrimination of von Willebrands disease (VWD) subtypes: Direct comparison of von Willebrand factor: Collagen binding activity/assay (VWF:CBA) with monoclonal antibody (MAB) based ELISA VWF-detection systems
61. Discrimination of von Willebrands disease (VWD) subtypes: Direct comparison of commercial ELISA-based options used to detect qualitative von Willebrand factor (VWF) defects
62. An ELISA test for the binding of von Willebrand antigen to collagen
63. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand's disease
64. von Willebrand's disease: Laboratory investigation using an improved functional assay for von Willebrand factor
65. Characterisation of plasma-derived and recombinant human VWF by improved collagen binding assays
66. Effect of multimerisation of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII
67. Abnormal collagen binding activity of 2A von Willebrand factor: Evidence that the defect depends only on the lack of large multimers
68. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay
69. Binding of von Willebrand factor to collagen by flow cytometry
70. Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations
71. Multicenter comparison of von Willebrand factor multimer sizing techniques. Report of the FVIII and von Willebrand factor subcommittee
72. Multimeric analysis of von Willebrand factor by vertical sodium docecyl sulphate agarose gel electrophoresis, vacuum blotting technology and sensitive visualisation by alkaline phosphatase anti-alkaline phosphatase complex
73. New variant of von Willebrand disease with defective binding to factor VIII
74. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: Significance and practical implications
75. Serial studies in von Willebrand's disease: Variability versus 'variants'
76. On laboratory problems in diagnosing mild von Willebrand's disease
77. Laboratory assessment of von Willebrand factor: Differential influence of prolonged ambient temperature specimen storage on assay results
78. von Willebrand's disease: Use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy
79. Expression of von Willebrand factor 'Normandy': An autosomal mutation that mimics as hemophilia A
80. The binding of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin and collagen and resides between amino acid residues Leu 512 and Lys 673
81. von Willebrand factor binds specifically to sulfated glycolipids
82. Sulfatide-binding assay for von Willebrand factor: Detection of von Willebrands disease without discrimination of VWD subtypes
83. Identification and characterisation of a novel mutation in von Willebrand Factor causing a Type 2B von Willebrand's disease